FDA Delays Decision on Cytokinetics Heart Drug; AstraZeneca Announces Positive Phase 3 Trial Results For Leading Medication.

The Food and Drug Administration (FDA) has delayed its decision regarding Cytokinetics’ heart drug. Separately, AstraZeneca announced Phase 3 trial results for one of its leading medications that could broaden the drug’s applications. The FDA’s decision on the Cytokinetics heart drug is now pending a later date, though the exact reason for the delay was not disclosed in the report. In other news, AstraZeneca reported that Phase 3 trial results could lead to expanded usage for one of its top-selling drugs. The company has not yet released detailed data from this trial, but indicated the results are positive and will be submitted to regulatory agencies for review.

Newsflash | Powered by GeneOnline AI
Date: May 2, 2025

Related posts:

GLP-1 Weight Loss Drugs Might Cause Blindness Duke University Engineers Develop AI Platform to Target “Undruggable” Diseases Study Reveals Brain’s Role in Regulating Ear Sensitivity and Compensating for Hearing Loss February Roundup: Key Executive Changes in the Healthcare Sector

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後